Search Results

You are looking at 91 - 100 of 161 items for :

  • "early breast cancer" x
  • All content x
Clear All
Full access

Ali Raza Khaki, V.K. Gadi, and Vinay Prasad

LA , Davis GJ , . Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer . J Clin Oncol 2001 ; 19 : 980 – 991 . 11181660 10.1200/JCO.2001.19.4.980 2. Wishart GC , Azzato EM , Greenberg

Full access

James O. Armitage, William C. Wood, and Dan L. Longo

-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial . J Clin Oncol 2014 ; 32 : 1188 – 1194 . 9. Early Breast

Full access

Azeez Farooki

meta-analysis . J Clin Oncol 2012 ; 30 : 513 . 4. Coleman R Gnant M Paterson A . Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: a meta-analysis of individual patient data

Full access

William J. Gradishar

) comparing one year of anti-HER2 therapy with lapatinib alone, trastuzumab alone, their sequence, or their combination in the adjuvant treatment of HER2-positive early breast cancer [abstract] . J Clin Oncol 2014 ; 32 ( Suppl 5 ): Abstract LBA4 . 4

Full access

Fiona Tsui-Fen Cheng, Fu Ou-Yang, Nina Lapke, Kai-Che Tung, Yen-Kung Chen, Yuh-Yu Chou, and Shu-Jen Chen

Regan MM Maiorano E . Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98 . J

Full access

Natasha Hunter, Sarah Croessmann, Karen Cravero, Daniel Shinn, Paula J. Hurley, and Ben Ho Park

predicts relapse in early breast cancer . Sci Transl Med 2015 ; 7 : 302ra133 . 26311728 10.1126/scitranslmed.aab0021 4. Higgins MJ , Jelovac D , Barnathan E , . Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood

Full access

NCCN Guidelines® Insights: Breast Cancer, Version 4.2021

Featured Updates to the NCCN Guidelines

William J. Gradishar, Meena S. Moran, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Sara A. Hurvitz, Steven J. Isakoff, Rachel C. Jankowitz, Sara H. Javid, Jairam Krishnamurthy, Marilyn Leitch, Janice Lyons, Jennifer Matro, Ingrid A. Mayer, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Kari B. Wisinski, Jessica S. Young, Jennifer L. Burns, and Rashmi Kumar

C , 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age . Lancet Oncol 2021 ; 22 : 476 – 488 . 10.1016/S1470

Full access

Amy A. Kirkham, Karen A. Gelmon, Cheri L. Van Patten, Kelcey A. Bland, Holly Wollmann, Donald C. McKenzie, Taryne Landry, and Kristin L. Campbell

care for early breast cancer . Oncologist 2018 ; 23 : 105 – 115 . 28982801 10.1634/theoncologist.2017-0141 15. Kirkham AA , Bonsignore A , Bland KA , . Exercise prescription and adherence for breast cancer: one size does not FITT all . Med

Full access

Pilar de la Morena Barrio, María Ángeles Vicente Conesa, Enrique González-Billalabeitia, Edgar Urrego, Elisa García-Garre, Elena García-Martínez, Marta Zafra Poves, Vicente Vicente, and Francisco Ayala de la Peña

. J Clin Oncol 2003 ; 21 : 976 – 983 . 2. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Peto R Davies C . Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome

Full access

Benjamin M. Parsons, Dipesh Uprety, Angela L. Smith, Andrew J. Borgert, and Leah L. Dietrich

-Gebhart MJ Gelber RD . 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial . Lancet 2017 ; 389 : 1195 – 1205 . 14. Joensuu H Kellokumpu